Donation

Resource
Do you want to receive the latest myeloma news and research for free, directly in your email inbox? You can with the Myeloma Minute! Subscribe below to receive weekly email newsletters with up-to-the 'minute' information about multiple myeloma. The Myeloma Minute includes: …
September 19, 2018
Resource
Helpful to health professionals and patients alike, the IMF’s Concise Review provides an in-depth overview of myeloma, with a discussion of the epidemiology, pathophysiology, clinical features, treatment options, and new and emerging treatments.
October 25, 2018
Resource
The Understanding series of cancer information booklets clearly and easily explain multiple myeloma treatments and care. Free for download.
October 25, 2018
Resource
Designed to serve as consistent references in a concise manner, the IMF’s Tip Cards cover key topics, including treatment and care issues of interest to patients and caregivers.
October 25, 2018
Resource
A reference list of common acronyms and abbreviations that are used in myeloma.
October 25, 2018
Resource
This tool tracks drugs from discovery to development to FDA approval for myeloma.
October 25, 2018
Resource
We’ve partnered with Smart Patients, an online community where patients and caregivers affected by complex illness learn from each other about treatments, challenges, and how it all fits into the context of their experience.
October 25, 2018
Resource
Myeloma Manager™ provides a tool to capture laboratory results and display and print tables and charts to show how those results change over time. Other features include automatic backup of your data each time you shut down the program, calendars, and graph features such as plotting multiple tests…
October 25, 2018
Resource
This multicenter IMWG study identifies relapsed multiple myeloma patients who: have received at least three prior lines of therapy, are refractory to both an immunomodulatory drug (IMiD) and a proteasome inhibitor (PI), and have been exposed to an alkylating…
May 12, 2017
Resource
These consensus guidelines have been compiled with input from the Scientific Advisors of the International Myeloma Foundation. Their production involved several steps including: A 3-day Scientific Advisors meeting, during which each specific area was presented and discussed (May 2002…
October 03, 2003
Resource
Dear Reader A Message from the President Special Event Donor Appreciation Event   Scientific & Clinical…
January 29, 2013
Resource
This 2012 Myeloma Today, a multiple myeloma journal, is a Special Gala Report, covering the IMF’s 6th Annual Comedy Celebration. Click here to download Myeloma Today
November 01, 2012
Resource
Dear Reader ​A Message from the President Special Event Professor Jesús San-Miguel is recipient of the Tenth Robert A. Kyle Lifetime Achievement Award   Scientific & Clinical…
September 11, 2012
Resource
Dear Reader Like Living with a Bad Neighbor Scientific & Clinical "Report from ASCO 2012: New Results in Frontline and at Relapse" by Dr. Brian Durie]   Supportive Care…
July 06, 2012
Resource
Dear Reader A Message from the President Scientific & Clinical "Best of ASH 2011 Recap: What Patients Need to Know" by Dr. Brian Durie "2012 IMF Research Grants" by Dr. Robert Kyle "Relapsed Multiple Myeloma After…
April 24, 2012
Resource
Dear Reader A Message from the President Scientific & Clinical:  Dr. Morton Coleman Shares an Overview of His 45-Year Career in MM Dr. Noopur Raje…
December 18, 2011
Resource
On December 2, 2016, 7 members of the International Myeloma Foundation (IMF) Nurse Leadership Board convened in San Diego, California, in concurrence with the American Society of Hematology (ASH) Annual Meeting, to discuss the following topics as they relate to the current therapeutic landscape and…
December 02, 2016
Resource
Patients with myeloma are surviving longer and, therefore, may experience continuing effects of their disease and treatment. Through clinical experience, the International Myeloma Foundation Nurse Leadership Board (NLB) was aware that a specific set of needs exists in this patient population.…
August 24, 2011
Resource
Patients with multiple myeloma (MM) cope with short- and long-term side effects of the treatment as well as other conditions onset from the disease itself; and sometimes, comorbid health conditions. Symptoms may not be managed well due to many factors. This document includes patient-friendly…
October 04, 2017
Resource
Oncologic emergencies associated with multiple myeloma include myelosuppression (anemia, neutropenia, and thrombocytopenia), bone-related emergencies, and acute renal failure. This article reviews the pathophysiology of these multiple myeloma-associated oncology emergencies and provides a framework…
October 04, 2017
Resource
About 85% of patients with multiple myeloma develop bone disease. In these patients, lytic bone lesions can cause fractures, poor circulation, blood clots, pain, poor mobility, and decreased quality of life. This article presents consensus statements to guide nurses in the assessment and management…
October 04, 2017
Resource
Venous thromboembolism (VTE) and cardiovascular (CV) disease can occur in patients with multiple myeloma. Although VTE and CV disease are separate medical conditions, they can be serious and even life-threatening.
October 04, 2017
Resource
Renal, GI, and Peripheral Nerves: Evidence-Based Recommendations for the Management of Symptoms and Care for Patients With Multiple Myeloma
October 04, 2017
Resource
The psychological needs of patients and caregivers may be inadvertently overlooked, contributing to the patient’s distress and possibly compromising outcomes. Untreated, these psychological needs may impair the patient’s ability to make decisions and adhere to treatment.
October 04, 2017
Resource
​Patients with multiple myeloma (MM) often deal with short- and long-term side effects of the treatment and disease sequelae. Reasons for inadequately managed symptoms are multifactorial (e.g., the patient may fear treatment interruption, the clinician does not assess or address the symptoms) and…
October 04, 2017
Resource
Background: One constant and relatively unchanged aspect of treatment of multiple myeloma (MM) is the use of glucocorticosteroids, or steroids, which can cause a wide range of adverse side effects and harm patients’ quality of life. Objectives: The objective of…
March 28, 2017
Resource
This 2011 Myeloma Today, a multiple myeloma journal, is a Special Gala Report, covering the IMF’s 5th Annual Comedy Celebration. Click here to download Myeloma Today
November 15, 2011
Resource
Dear Reader:  A Message from the President Scientific & Clinical IMF's International Myeloma Working Group; The Annual IMWG Summit The Role of Protein Electrophoresis Testing in Myeloma - Myeloma…
October 11, 2011
Resource
  Dear Reader  A Message from the President Scientific & Clinical Myeloma Today in Conversation with C. Ola Landgren, MD, PhD The Current Role of Serum Free Light Chain Analysis in Myeloma - Myeloma Today in…
June 30, 2011
Resource
  Dear Reader:  Looking back over the last 20 years. Board of Directors: The IMF Board of Directors welcomes its newly elected members Donna Feig John A. O'Dwyer Dr. S. Vincent Rajkumar …
March 30, 2011
Resource
This 2010 Myeloma Today, a multiple myeloma cancer journal, is a Special Gala Report, covering the IMF’s 4th Annual Comedy Celebration. Click here to download Myeloma Today
March 02, 2011
Resource
Published in the Journal of the Advanced Practitioner in Oncology (JADPRO), this guide is a continuing education activity for health-care professionals. It provides the latest scientific information on effectively managing the care of multiple myeloma patients.
March 25, 2016
Resource
Managing the patient with multiple myeloma (MM) across the continuum of care is challenging given the heterogeneity of the population. Provided are IMF Patient Education Tools. These fact sheets discuss side effects that may result from the use of novel agents in multiple myeloma, and how to manage…
October 28, 2015
Resource
Written by the IMF Nurse Leadership Board, made up of experienced specialty oncology nurses, these are the first comprehensive guidelines for managing side effects from lenalidomide, thalidomide, and bortezomib used in the treatment of multiple myeloma. Published in the June 2008,…
October 22, 2015
Resource
Autologous hematopoietic stem cell transplantation (AHSCT) is an approved for the treatment for multiple myeloma. This article provides non-transplantation oncology nurses with guidelines for education, clinical management, and support of patients with multiple myeloma undergoing AHSCT. It provides…
December 17, 2013
Resource
This report compiles notes from roundtable meeting of members of the International Myeloma Foundation (IMF) Nurse Leadership Board who convened at the December 6th American Society of Hematology (ASH) Annual Meeting. They discussed treatment best practices for using VELCADE® in multiple myeloma (MM…
December 06, 2013
Resource
Dear Reader A Message from the President Scientific & Clinical The Current Role of Transplantation in Multiple Myeloma: Myeloma Today in conversation with Dr. Cristina Gasparetto Bone Disease in Multiple…
December 25, 2010
Resource
Dear Reader A Message from the President News and Notes Obesity and risk of MGUS MGUS and risk of skeletal fractures Myeloma-associated chromosomal abnormalities Arterial thrombosis in…
November 14, 2010
Resource
Dear Reader  A Message from the President Scientific & Clinical  Cure versus Control: Myeloma Today in conversation with Dr. S. Vincent Rajkumar  Induction Therapy Prior to Autologous Stem Cell…
July 06, 2010
Resource
Dear Reader  A Message from the President  IMF Welcomes Daniel Navid as Senior Global Analyst Board of Directors The IMF Welcomes Entertainment Industry Executive to Board of Directors; Myeloma…
April 12, 2010
Resource
One of the most daunting aspects of being diagnosed with myeloma is learning about an unfamiliar disease that is quite complicated. The IMF’s Patient Handbook for the Newly Diagnosed provides an overview of myeloma, with a focus on getting the correct diagnosis and…
January 02, 2019
Resource
This IMWG consensus provides recommendations on the use of 18fluorodeoxyglucose (18F-FDG) PET/CT in multiple myeloma patients and other plasma cell disorders, including smoldering multiple myeloma and solitary plasmacytoma. (18F-FDG) PET/CT assesses bone damage with relatively high sensitivity…
April 06, 2017
Resource
Life expectancy for multiple myeloma patients has increased since the introduction of autologous stem cell transplantation and novel agents. While positive, longer life expectancy also relates to greater risk of second primary malignancies. This summary reviews current information about possible…
January 24, 2017
Resource
The International Myeloma Working Group consensus updates the definition for high-risk (HR) multiple myeloma based on cytogenetics Several cytogenetic abnormalities such as t(4;14), del(17/17p), t(14;16), t(14;20), nonhyperdiploidy, and gain(1q) were identified that confer poor prognosis. The…
June 16, 2016
Resource
Recommendations developed by the International Myeloma Working Group (IMWG), the research arm of the IMF, were published online in the Journal of Clinical Oncology on March 14, 2016. The recommendations are based on data gathered through December 2015 and analyzed by Meletios A. Dimopoulos, MD,…
March 15, 2016
Resource
The prognosis for patients multiple myeloma (MM) has improved substantially over the past decade with the development of new, more effective chemotherapeutic agents and regimens that possess a high level of anti-tumor activity. In spite of this important progress, however, nearly all MM patients…
December 29, 2015
Resource
This study provides the most current information for patients with multiple myeloma who are not eligible for autologous stem-cell transplantation. It aims to aid clinicians to ensure that patients with myeloma receive the most appropriate care in everyday clinical practice. The study finds that…
February 20, 2014
Resource
Even though the landscape for multiple myeloma diagnosis and management has substantially developed in the past 10 years, the clinical guidelines that provide recommendations on standard treatment for myeloma patients does not take into account the limitations of resources in developing countries.…
November 14, 2013
Resource
Now more than ever before, multiple myeloma patients are assessed and treated more precisely. New technologies are now able to “evaluate the biology and extent of the disease,” including the following: cytogenetic information genetic abnormalities extramedullary…
June 23, 2013
Resource
This study seeks to “assess the independent contributions of International Staging System (ISS) stage and cytogenetic abnormalities in predicting outcomes. This international effort used the International Myeloma Working Group database of 12,137 patients treated worldwide for myeloma at diagnosis,…
March 27, 2013

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.